Last edition
News about "immune-mediated disease programme"
Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies
Johnson & Johnson has entered into a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases that includes a USD 465 million equity investment, milestone-based payments and an exclusive option to acquire Sail Biomedicines for USD 2.58 billion.
Immune-mediated Disease Programme | 31/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members